July 2017

New Indications

Halaven (eribulin mesilate) is now indicated for the treatment of unresectable liposarcoma in patients who have received prior chemotherapy for advanced or metastatic disease.

Keytruda (pembrolizumab (rch)) is now indicated for the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in patients whose tumours express PD-L1 with a ≥ 50% tumour proportion score (TPS) as determined by a validated test, with no EGFR or ALK genomic tumour aberrations.

Keytruda is now indicated for the treatment of advanced NSCLC in patients whose tumours express PD-L1 with a ≥ 1% TPS as determined by a validated test and who have received platinum containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have received prior therapy for these aberrations prior to receiving Keytruda.

Keytruda is now indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum containing chemotherapy.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au